Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225315 | 0.88 | — | — | |
| SCHEMBL5733012 | 0.87 | TSHR (0.38) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL7794644 | 0.83 | — | — | |
| SCHEMBL11259548 | 0.83 | TSHR (0.52) | ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL7792166 | 0.81 | TSHR (0.50) | CYP2C19CYP1A2ALDH1A1TSHR | |
| SCHEMBL16716017 | 0.80 | — | — | |
| SCHEMBL13630903 | 0.79 | KDM4E (0.33) | CYP2C19MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL8025616 | 0.78 | CA12 (0.50) | CYP2C19MEN1KMT2ACYP1A2CA12 | |
| SCHEMBL9419694 | 0.75 | CYP2C19 (0.40) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL13246677 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321287-A1 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20220008568-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-01-13 | — | — | US | disclosed |
| US-20210346528-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2021-11-11 | — | — | US | disclosed |
| US-20210346529-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2021-11-11 | — | — | US | disclosed |
| US-11083805-B2 | Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2021-08-10 | — | — | US | disclosed |
| EP-3536347-A1 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER | Advanced Accelerator Applications USA, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-2900279-B1 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER | ADVANCED ACCELERATOR APPLICATIONS USA INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20180133349-A1 | Radiolabeled GRPR-Antagonists For Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2018-05-17 | — | — | US | disclosed |
| US-20180133349-A1 | Radiolabeled GRPR-Antagonists For Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2018-05-17 | — | — | US | disclosed |
| US-9839703-B2 | Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer | ADVANCED ACCELERATOR APPLICATIONS USA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839703-B2 | Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer | ADVANCED ACCELERATOR APPLICATIONS USA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20150265732-A1 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2015-09-24 | — | — | US | disclosed |
| US-20150265732-A1 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150265732-A1 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER | GRPR, GIPR, CCKBR | CYP2C19 4173/4885MEN1 335/4885GLA 499/4885 |
| US-20180133349-A1 | Radiolabeled GRPR-Antagonists For Diagnostic Imaging and Treatment of GRPR-Positive Cancer | GRPR, GIPR, CCKBR | CYP2C19 4231/4885MEN1 253/4885GLA 433/4885 |
| US-20210346528-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | GRPR, GIPR, CCKBR | CYP2C19 4231/4885MEN1 253/4885GLA 433/4885 |
| US-20210346529-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | GRPR, GIPR, CCKBR | CYP2C19 4231/4885MEN1 253/4885GLA 433/4885 |
| US-20220008568-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | GRPR, GIPR, CCKBR | CYP2C19 4231/4885MEN1 253/4885GLA 433/4885 |
| US-11083805-B2 | Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer | GRPR, GIPR, CCKBR | CYP2C19 4231/4885MEN1 253/4885GLA 433/4885 |
| US-20230321287-A1 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | GRPR, GIPR, SCTR | CYP2C19 2794/4885MEN1 180/4885GLA 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.